Description: DaVita (DVA) just finalized an amended credit agreement that brings in a $2 billion five-year term loan and a $1.5 billion revolving credit facility. This refinancing not only repays previous debt, but also offers additional financial flexibility for corporate needs. See our latest analysis for DaVita. DaVita’s recent credit agreement comes as the stock has struggled to regain its footing, with a year-to-date share price decline of 20.1% and a 12-month total shareholder return of -28%. While...

Description: DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Description: NORTHAMPTON, MA / ACCESS Newswire / November 28, 2025 / DaVita Earlier this year, more than 100 DaVita teammates (employees) from across the country gathered in Florida for the inaugural DaVita Recess, a two-day immersive experience designed to celebrate ...

Description: AllianceBernstein Global High Income Fund, Inc.[NYSE: AWF] (the "Fund") today released its monthly portfolio update as of October 31, 2025.

Description: The shares have been on a tear lately, buoyed by optimism about Google’s use of artificial intelligence in its search business.

Description: DaVita's consensus analyst price target has been revised downward from $147.13 to $144.50. This change signals a modest adjustment in the market's outlook. The shift reflects an ongoing reassessment of factors influencing the company's valuation, including both strengths in its business fundamentals and continuing external uncertainties. Stay tuned for guidance on how to follow future updates as DaVita's narrative continues to develop. Stay updated as the Fair Value for DaVita shifts by...

Description: Wondering if DaVita stock is trading at a bargain or an inflated premium? You are not alone, especially with so much chatter about where opportunities really lie in this market. Despite impressive gains of 62.7% across three years, DaVita’s stock has stumbled more recently, with a one-year drop of 27.3% and a decline of 19.7% year-to-date. Recent headlines have shone a spotlight on DaVita’s evolving operating environment, especially as healthcare policy debates and shifting competitive...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to

Description: DaVita Inc. (NYSE: DVA) today announced that its chief financial officer, Joel Ackerman, will participate in a fireside chat at the Wolfe Research Healthcare Conference on Monday, November 17, 2025, at 11:20 am EST. To view the live webcast, visit the Wolfe Research page here and create a free registration.

Description: Earlier this week, DaVita unveiled six new clinical studies at the American Society of Nephrology Kidney Week 2025 in Houston, covering advancements in dialysis treatments, middle molecule clearance, and initiatives such as GLP-1 receptor agonists for reducing hospitalizations in end-stage kidney disease patients. One standout research effort was developed through DaVita's unique program that partners with independent medical directors, helping ensure new clinical studies are deeply informed...

Description: NORTHAMPTON, MA / ACCESS Newswire / November 12, 2025 / DaVita On Nov. 13, DaVita launches its Caring Across Communities initiative, a weeklong service event dedicated to strengthening local communities across California. Through Nov. 19, nearly ...

Description: We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing . DaVita Inc. (NYSE:DVA) is one of the stocks Jim Cramer recently discussed. DaVita Inc. (NYSE:DVA) is a healthcare company that caters to the needs of kidney patients. Cramer made these remarks after co-host Carl Quintanilla discussed the […]

Description: We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Oscar Health, Inc. (NYSE:OSCR) is one of the stocks Jim Cramer recently discussed. Oscar Health, Inc. (NYSE:OSCR) is a mid-sized healthcare benefits company. It was one of the worst-hit stocks yesterday as the shares closed 17.6% lower. Cramer […]

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at DaVita expected to complete in the fourth quarter; Access for 275,000 total patients across customer base expected by year-end Vadadustat post-hoc data analysis presented at ASN Kidney Week demonstrates composite of all-cause mortality and hospitalization outcomes statistically more favorable for patients receiving vadadustat compared to ES

Description: DaVita has considerably underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Description: DaVita’s third quarter results drew a negative reaction from the market, as the company’s profit and margins fell short of analyst expectations despite meeting revenue forecasts. Management attributed the underperformance primarily to lower treatment volumes, which declined due to a combination of a severe flu season, the impact of Hurricane Helene, and disruptions from a cyber incident. CEO Javier Rodriguez highlighted ongoing cost management and continued investment in clinical innovation, but

Description: DaVita, a steadfast leader in kidney care research and innovation, is unveiling six new studies at the American Society of Nephrology's (ASN) Kidney Week 2025, taking place Nov. 5-9 in Houston, Texas. These studies reflect DaVita's ongoing commitment to advancing kidney treatment through data-driven insights — spanning dialysis treatments, including emerging pathways to middle molecule clearance, and expanding access to transplantation, end-of-life care and more. As DaVita celebrates 25 years of

Description: Ever wondered if DaVita is actually a bargain hiding in plain sight? Let’s dive into what might be driving its current price and value story. After a solid run in recent years, DaVita’s stock is down 8.1% over the past week and has slipped 20.6% since January. This has made value-focused investors sit up and take notice. Recently, headlines have focused on changing dynamics in the U.S. healthcare sector and regulatory shifts that could impact dialysis providers. This added context helps...

Description: DaVita (DVA) shares have seen mixed trading over the past month, with the stock down around 9%. While no single headline event is driving recent moves, the company’s fundamentals have piqued investor interest. This has prompted a closer look at current valuations. See our latest analysis for DaVita. After a sharp slide in recent weeks, DaVita’s share price is now down more than 20% since the start of the year, reflecting some fading momentum. Despite this pullback, the company’s three-year...

Description: Warren Buffett's Berkshire Hathaway owns dozens of stocks, but these are the three you should pounce on.

Description: DVA's Q3 earnings miss estimates despite revenue growth, as margins tightened and shares slipped post-results.

Description: Dialysis provider DaVita Inc. (NYSE:DVA) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.8% year on year to $3.42 billion. Its non-GAAP profit of $2.51 per share was 20.9% below analysts’ consensus estimates.

Description: Nic Eliason: Thank you, and welcome to our third quarter conference call. Please note that during this call, we may make forward-looking statements within the meaning of the federal securities laws. All of these statements are subject to known and unknown risks and uncertainties, that could cause the actual results to differ materially from those described in the forward-looking statements.

Description: Dialysis provider DaVita Inc. (NYSE:DVA) met Wall Streets revenue expectations in Q3 CY2025, with sales up 4.8% year on year to $3.42 billion. Its non-GAAP profit of $2.51 per share was 20.9% below analysts’ consensus estimates.

Description: DaVita HealthCare (DVA) delivered earnings and revenue surprises of -23.71% and +0.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2025.

Description: ​DaVita Inc. (NYSE:DVA) is one of the Best 52-Week Low Mid Cap Stocks to Buy Now. On October 14, David MacDonald from Truist lowered the firm’s price target on DaVita Inc. (NYSE:DVA) from $148 to $140, while keeping a Hold rating on the stock. ​The analyst noted that they remain broadly bullish on the healthcare […]

Description: DVA's third-quarter 2025 performance is likely to benefit from technology upgrades and cost control while battling high missed treatments and low volume growth.

Description: SAN JOSE, CALIFORNIA / ACCESS Newswire / October 28, 2025 / VSee Health, Inc.(Nasdaq:VSEE) (the "Company"), announced it has received its Authority to Operate (ATO) at the FedRAMP High level from the U.S. Department of Health and Human Services (HHS). ...

Description: Dialysis provider DaVita Inc. (NYSE:DVA) will be announcing earnings results this Wednesday after market hours. Here’s what investors should know.

Description: AllianceBernstein Global High Income Fund, Inc. [NYSE: AWF] (the "Fund") today released its monthly portfolio update as of September 30, 2025.

Description: These bargains could prove good for your financial health.

Description: DaVita HealthCare (DVA) concluded the recent trading session at $128.05, signifying a +1.72% move from its prior day's close.

Description: DaVita will release its third-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

Description: The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.